NeuroSearch advises that the indictment concerning

Announcement 29.07.2013 Reference is made to announcement no. 21-13 of 17 July 2013 in which NeuroSearch A/S (NEUR) announced that the company is being prosecuted by the Danish Public Prosecutor for Special Economic and International Crimes (SEIC) for alleged qualified share price manipulation. In the indictment, which was released today, SEIC states that prosecution is initiated against NeuroSearch as a legal entity and the CEO employed in company at the time of the alleged share price manipulation. Thus, neither the present Management nor members of the present and former Board of Directors have been prosecuted. For further information, NeuroSearch refers to the indictment and the Danish Public Prosecutor for Special Economic and International Crimes. On the present basis, NeuroSearch denies the charges and fully collaborates with the authorities to resolve the matter. René Schneider CEO Contact person René Schneider, CEO, telephone: +45 2911 2097 About NeuroSearch NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II, and NS2359 which has completed phase I. All drug candidates exert their effect in the central nervous system.